Pay in 4 interest-free payments of $7.24 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Understanding the Expanded Risk Data: The Mass Eye & Ear study analyzed years of clinical data and discovered that the risk of developing this debilitating form of blindness was profoundly higher for individuals prescribed a form of semaglutide, including Ozempic, Wegovy and Rybelsus: For Diabetic Patients: Individuals using Ozempic for Type 2 diabetes were found to be 4 times more likely to be diagnosed with NAION compared to those on non-GLP-1 diabetes therapies
This research area has attracted sustained scientific attention and continues to generate active laboratory investigation
Verify consistent timing
The objective of the study was to assess the risk of semaglutide leading to various serious adverse events (SAEs), including blood clots, in patients with type 2 diabetes
A number quoted in an article is a snapshot of a moving target
Presented at: American Diabetes Association Scientific Sessions
US$ 20.33
US$ 27.28
US$ 27.19
US$ 25.15
US$ 28.06
